Similar to our first quarter earnings call, our prepared remarks tonight will focus on achievements and opportunities by end ...
Essex Property Trust, Inc. (NYSE:ESS) (the "Company") announced today its fourth quarter and full-year 2024 earnings results and related business activities. Net ...
High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) ...
High probability of technical success in pivotal Phase 3 trial based on unmatched efficacy data for third-line non-small cell lung cancer (NSCLC) treatment FDA's Fast Track designation for ateganosine ...
Why this new architecture was the best thing at CES 2026. What is a dataflow architecture? Why Efficient Computer’s Electron E1 processor design is so radical. How the Electron E1 is able to be so ...
Background: Programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors combined with chemotherapy represent the standard first-line treatment for stage IV non-small cell ...
Enhertu showed improved iDFS over Kadcyla in early-stage HER2-positive breast cancer with residual disease post-neoadjuvant therapy. Enhertu's iDFS benefits were consistent across HER2 expression ...
Dr. Michael Wang discusses ECHO long-term data, revealing that concurrent therapy for mantle cell lymphoma significantly outperforms sequential treatment. The global ECHO trial, initiated in 2017, ...
Acalabrutinib was associated with increased PFS and a 24% reduction in time to next treatment or death in long-term results. Concurrent acalabrutinib, bendamustine, and rituximab (ABR) in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results